|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical R&D Outsourcing Strategies: An Analysis of Market Drivers and Resistors to 2010
Business Insights, Sep 2002
Shareholder appetite for growth has not diminished, in stark contrast to the pharmaceutical industry's ability to generate return on capital employed while R&D and sales and marketing have traditionally been held sacred as core competencies, the time has to come to reassess this assumption and the alternative - outsourcing. The Pharmaceutical R&D Outsourcing Strategies report provides insights into effective outsourcing across the value chain, from drug discovery through to regulatory submission. Through a series of case studies it outlines outsourcing best practice and it examines the role of new technologies in increasing the effectiveness of R&D outsourcing. Based on an extensive programme of research, including interviews with senior pharmaceutical industry executives, this new report presents a route map for high-performance outsourcing.
Key findings...
- Of the 44 products generating blockbuster sales in 2000, 33 will lose patent protection in the US before 2007, exposing approximately $45.5bn of US ethical revenues to generic competition.
- Estimates of the proportion of clinical development (phase I-IV) out sourced vary between 20-40%, whilst many analysts estimate that less than 15% of pre-clinical evaluations are outsourced
- An effective outsourcing strategy will determine the optimal level of in-house versus outsourced R&D activity and maintain this, allowing for fluctuations in resource demands.
- Whilst the larger CROs have been adding additional services to their portfolios in an attempt to act as one-stop-shops, it is clear that many pharmaceutical sponsors are not yet comfortable with outsourcing entire portions of their R&D activities to single providers.
This report can help you to gain..
- A detailed understanding of the financial pressures on CROs and the likely impact on the industry's structure
- A broader perspective on the relationship between M&A, outsourcing and R&D efficiency
- Insights into the practical realities of developing a virtual pharmaceutical company
- Answers to your questions about web-enabling technologies, from e-detailing to in silico research
- Specific knowledge of 'facility-for-service' deals, including Quintiles/Aventis
- Access to the latest strategies on what makes outsourcing work.
Your outsourcing questions answered
- What is driving outsourcing forward - and what's holding it back?
- How are the world's biggest pharmaceuticals companiesapproaching R&D outsourcing?
- What are the key considerations when making the decision to outsource?
- How do we ensure maximum ROI in outsourcing?
- What are the risks in outsourcing and how can we minimise them?
- How are CROs evolving - what is the impact on our business?
Key features of the report
- Industry forecasts to 2010 - offering an insight into the future development and growth of pharmaceutical outsourcing
- Detailed market size data 1999-2001 - providing a snapshot of the outsourcing industry's recent performance
- CRO competitor profiles - outlining the major CROs, their competencies and service offerings
- Concise case studies - demonstrating different approaches and outsourcing best practice
- Executive survey - presenting consolidated evidence from senior decision makers of the industry's expectations from outsourcing
- Analysis of deal structures - focusing on the strengths and weaknesses of different fee systems
Customers who bought this item also bought
Clinical Operations: Benchmarking Per-Patient Trial Costs, Staffing and Adaptive Design
Investigating Clinical Trial Costs: Comparative Analysis of Trial Cost Components in Key Geographies
Guide to Pharmaceutical Outsourcing in China: A Handbook for Pharmaceutical and Biotechnology Companies Planning to Outsource to China
A Quick Guide to Clinical Trials for People Who May Not Know It All
The Voice of the Site Coordinator
Global CRO Spending Trends
2010 CRO Quality Benchmarking Report
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
Late Phase Dynamics
Innovations and Trends in Clinical Trials - Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
|
|
|
|
